Back to News
Market Impact: 0.3
Orca Bio Announces the Publication of TREGZI™ Long-Term Overall Survival Data in Transplantation and Cellular Therapy
Source: Business Wire
Healthcare & Biotech
Three-year data indicated that TREGZI™ may improve overall survival versus post-transplant cyclophosphamide in patients with hematologic malignancies. The reported survival benefit is clinically positive, though the release provides no numerical efficacy data, safety results, trial details, or commercial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Deutsche Bank downgrades Novartis stock rating to sell on valuation